Dimebon + omeprazole (DrugBank: Omeprazole, Dimebon)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
8 | ハンチントン病 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00931073 (ClinicalTrials.gov) | July 2009 | 1/7/2009 | A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers | A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM Subjects | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon alone;Drug: Dimebon + Ketoconazole;Drug: Dimebon + Omeprazole | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 24 | Phase 1 | United States |